Isotechnika Reports Final Results of the PROMISE Trial
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. (TSX:ISA) today announced positive results from the Phase 2b PROMISE trial which evaluated the Company's lead drug, voclosporin , in de novo kidney transplant patients. This trial was designed to determine the most appropriate dosing strategy for the Phase 3 program in kidney transplantation. "PROMISE has shown that the efficacy of voclosporin is statistically ...